Jump to content

Hang Yin (scientist): Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Qr972500 (talk | contribs)
146 edits
Undid revision 857238654 by Qr972500 (talk)
Rescuing 2 sources and tagging 0 as dead.) #IABot (v2.0.9.5
 
(10 intermediate revisions by 9 users not shown)
Line 13: Line 13:
|workplaces = [[Tsinghua University]]
|workplaces = [[Tsinghua University]]
|alma_mater = [[Yale University]]
|alma_mater = [[Yale University]]
|doctoral_advisor = [[Andrew D. Hamilton]]
|doctoral_advisor =
|academic_advisors =
|academic_advisors =
|doctoral_students =
|doctoral_students =
Line 27: Line 27:
|footnotes =
|footnotes =
}}
}}
'''Hang Hubert Yin''' (born 5 July 1976) is a professor of pharmaceutical sciences at [[Tsinghua University]], a recipient of several young scientist awards for his research in [[chemical biology]] and [[drug discovery]].
'''Hang Hubert Yin''' (born 5 July 1976) is a professor and deputy dean of pharmaceutical sciences at [[Tsinghua University]], a recipient of several young scientist awards for his research in [[chemical biology]] and [[drug discovery]].<ref>{{cite web|title=Yin Group Website|url=http://www.sps.tsinghua.edu.cn/yinlab/Index.html|access-date=2018-11-07|archive-date=2018-11-07|archive-url=https://web.archive.org/web/20181107185435/http://www.sps.tsinghua.edu.cn/yinlab/Index.html|url-status=dead}}</ref>


==Career==
==Career==
Hang Hubert Yin was a pupil at the [[High School of Peking University]]. After studying for a bachelor's degree at the [[Peking University]], he received his [[PhD]] from [[Yale University]], [[New Haven]] in 2004 (supervisor: Professor [[Andrew D. Hamilton]] [[Fellow of the Royal Society|FRS]]) and then spent a post-doctoral period at the [[University of Pennsylvania School of Medicine]] under the supervision of Professor [[William DeGrado]].<ref>{{cite web|title=Yin AACR Bio|url=http://www.aacr.org/home/public--media/stand-up-to-cancer/su2c-innovative-research-grants/2009-innovative-research-grants/innovative-research-grants-investigator-biographies.aspx|deadurl=yes|archiveurl=https://web.archive.org/web/20120625204419/http://www.aacr.org/home/public--media/stand-up-to-cancer/su2c-innovative-research-grants/2009-innovative-research-grants/innovative-research-grants-investigator-biographies.aspx|archivedate=2012-06-25|df=}}</ref> In 2007, he joined the faculty of the [[University of Colorado Boulder]]. His research interests lie at the interface of [[chemistry]], [[biology]], and [[engineering]] with particular focuses on [[structure-based drug design]], [[cell signaling]] [[biochemistry]], [[biotechnology]] development, and [[membrane protein]] simulations.<ref>{{cite web|title=Yin Research Group Website|url=http://www.sps.tsinghua.edu.cn/cn/team/team/2017/1221/104.html}}</ref>
Hang Hubert Yin was a pupil at the [[High School of Peking University]]. After studying for a bachelor's degree at the [[Peking University]], he received his [[PhD]] from [[Yale University]], [[New Haven]] in 2004 and then spent a post-doctoral period at the [[University of Pennsylvania School of Medicine]] under the supervision of Professor [[William DeGrado]].<ref>{{cite web|title=Yin AACR Bio|url=http://www.aacr.org/home/public--media/stand-up-to-cancer/su2c-innovative-research-grants/2009-innovative-research-grants/innovative-research-grants-investigator-biographies.aspx|url-status=dead|archiveurl=https://web.archive.org/web/20120625204419/http://www.aacr.org/home/public--media/stand-up-to-cancer/su2c-innovative-research-grants/2009-innovative-research-grants/innovative-research-grants-investigator-biographies.aspx|archivedate=2012-06-25}}</ref> In 2007, he joined the faculty of the [[University of Colorado Boulder]]. His research interests lie at the interface of [[chemistry]], [[biology]], and [[engineering]] with particular focuses on [[structure-based drug design]], [[cell signaling]] [[biochemistry]], [[biotechnology]] development, and [[membrane protein]] simulations.<ref>{{cite web|title=Yin Research Group Website|url=http://www.sps.tsinghua.edu.cn/cn/team/team/2017/1221/104.html}}</ref>


==Awards==
==Awards==
*[[American Chemical Society]] David W. Robertson Award for Excellence in Medicinal Chemistry (2016)<ref>{{cite web|title=ACS MEDI|url=https://www.acsmedchem.org/?nd=robertsonaward}}</ref>
*[[American Chemical Society]] David W. Robertson Award for Excellence in Medicinal Chemistry (2016)<ref>{{cite web|title=ACS MEDI|url=https://www.acsmedchem.org/?nd=robertsonaward}}</ref>
* CAPA Distinguished Junior Faculty Award (2012)<ref>{{cite web|title=Chinese-American Chemistry Professor Association website|url=http://capa-chem.webs.com/capaawards.htm}}</ref>
* CAPA Distinguished Junior Faculty Award (2012)<ref>{{cite web|title=Chinese-American Chemistry Professor Association website|url=http://capa-chem.webs.com/capaawards.htm|access-date=2012-08-25|archive-date=2013-01-05|archive-url=https://archive.today/20130105114057/http://capa-chem.webs.com/capaawards.htm|url-status=dead}}</ref>
* [[Stand Up to Cancer]] Innovative Research Grant Award (2010)<ref>{{cite web|title=SU2C news coverage|url=https://www.youtube.com/watch?v=GEenzig4QB4&feature=player_embedded}}</ref>
* [[Stand Up to Cancer]] Innovative Research Grant Award (2010)<ref>{{cite web|title=SU2C news coverage| website=[[YouTube]] |url=https://www.youtube.com/watch?v=GEenzig4QB4&feature=player_embedded}}</ref>
* [[National Science Foundation]] CAREER Award (2010)<ref>{{cite web|title=University of Colorado Boulder news coverage|url=http://www.colorado.edu/news/releases/2010/03/18/six-cu-boulder-professors-win-national-science-foundation-career-awards}}</ref>
* [[National Science Foundation]] CAREER Award (2010)<ref>{{cite web|title=University of Colorado Boulder news coverage|url=http://www.colorado.edu/news/releases/2010/03/18/six-cu-boulder-professors-win-national-science-foundation-career-awards|access-date=2012-08-25|archive-url=https://web.archive.org/web/20120730105148/http://www.colorado.edu/news/releases/2010/03/18/six-cu-boulder-professors-win-national-science-foundation-career-awards|archive-date=2012-07-30|url-status=dead}}</ref>
* [[American Association for Cancer Research]] [[Gertrude B. Elion]] Cancer Research Award (2009)<ref>{{cite web|title=Elion Award lecture|url=http://www.colorado.edu/chem/yinlab/Pages/PDF%20FIles/Elion%20Lectureship%20Page.pdf}}</ref>
* [[American Association for Cancer Research]] [[Gertrude B. Elion]] Cancer Research Award (2009)<ref>{{cite web|title=Elion Award lecture|url=http://www.colorado.edu/chem/yinlab/Pages/PDF%20FIles/Elion%20Lectureship%20Page.pdf|access-date=2012-08-26|archive-url=https://web.archive.org/web/20120803080737/http://www.colorado.edu/chem/yinlab/Pages/PDF%20FIles/Elion%20Lectureship%20Page.pdf|archive-date=2012-08-03|url-status=dead}}</ref>
* University of Colorado New Inventor of the Year (2009)<ref>{{cite web|title=University of Colorado Technology Transfer Office news coverage|url=https://www.cu.edu/content/cuannouncesannualtechnologytransferawards|archive-url=https://archive.is/20121210194417/https://www.cu.edu/content/cuannouncesannualtechnologytransferawards|dead-url=yes|archive-date=2012-12-10}}</ref>
* University of Colorado New Inventor of the Year (2009)<ref>{{cite web|title=University of Colorado Technology Transfer Office news coverage|url=https://www.cu.edu/content/cuannouncesannualtechnologytransferawards|archive-url=https://archive.today/20121210194417/https://www.cu.edu/content/cuannouncesannualtechnologytransferawards|url-status=dead|archive-date=2012-12-10}}</ref>
* [[National Institute on Drug Abuse]] ECHEM Award (2009)
* [[National Institute on Drug Abuse]] ECHEM Award (2009)
* [[National Institute on Drug Abuse]] CEBRA Award (2009)
* [[National Institute on Drug Abuse]] CEBRA Award (2009)
* [[Sidney Kimmel]] Scholars Award (2008)<ref>{{cite web|title=University of Colorado Boulder news coverage|url=http://www.colorado.edu/news/releases/2008/03/22/cu-boulder-professor-receives-200000-kimmel-scholar-award-cancer-research}}</ref>
* [[Sidney Kimmel]] Scholars Award (2008)<ref>{{cite web|title=University of Colorado Boulder news coverage|url=http://www.colorado.edu/news/releases/2008/03/22/cu-boulder-professor-receives-200000-kimmel-scholar-award-cancer-research|access-date=2012-08-25|archive-url=https://web.archive.org/web/20120730105153/http://www.colorado.edu/news/releases/2008/03/22/cu-boulder-professor-receives-200000-kimmel-scholar-award-cancer-research|archive-date=2012-07-30|url-status=dead}}</ref>
* [[Howard Hughes Medical Institute]] Collaborative Innovation Award (2008)<ref>{{cite web|title=Howard Hughes Medical Institute news coverage|url=http://www.hhmi.org/news/rees_20081120.html}}</ref>
* [[Howard Hughes Medical Institute]] Collaborative Innovation Award (2008)<ref>{{cite web|title=Howard Hughes Medical Institute news coverage|url=http://www.hhmi.org/news/rees_20081120.html}}</ref>


==Significant contributions==
==Significant contributions==
Yin's team showed that [[morphine]] causes [[inflammation]] by binding to the protein [[lymphocyte antigen 96]], which, in turn, causes the protein to bind to an [[immune]] system receptor called [[Toll-like receptor 4]] ([[TLR4]]).<ref>[http://www.nature.com/nature/journal/v484/n7395/full/484419a.html Making morphine work better, Nature 2012, 484: 419]</ref> The morphine-induced TLR4 activation attenuates [[pain]] suppression by [[opioid]] and enhances the development of opioid [[Drug tolerance|tolerance]] and [[addiction]], [[drug abuse]], and other negative side effects such as [[respiratory depression]]. The Yin group has developed drug candidates that can improve opioid-based [[pain management]] therapies.<ref>[http://cen.acs.org/articles/90/web/2012/08/Small-Molecules-Target-Toll-Like.html Drahl, C. Small Molecules Target Toll-Like Receptors, C&EN 2012, 90: 33]</ref> On June 23, 2014, [[BioLineRx]] Ltd. ([[NASDAQ]]: BLRX; [[TASE]]: BLRX) announced that it has in-licensed BL-1010, a novel compound for the treatment of neuropathic pain invented by Yin from the University of Colorado.<ref>{{cite press release|title=BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain|publisher=MarketWatch|url=http://www.marketwatch.com/story/biolinerx-in-licenses-novel-compound-for-treatment-of-neuropathic-pain-2014-06-23}}</ref> In 2015, Yin reported a new drug candidate that could change the way [[Parkinson's disease]] is treated.<ref>[http://www.colorado.edu/chem/yinlab/Pages/PDF%20FIles/Science%20Highlights.pdf Making Aggregation Less Aggravating, Science 2015, 348: 769]</ref> The drug, called CU-CPT22, may help stop harmful inflammation in certain immune cells that is thought to cause Parkinson's.<ref>{{cite web|title=CU Parkinson's research could revolutionize treatment|url=http://www.thedenverchannel.com/news/cu-parkinsons-research-could-revolutionize-treatment}}</ref>
Yin's team showed that [[morphine]] causes [[inflammation]] by binding to the protein [[lymphocyte antigen 96]], which, in turn, causes the protein to bind to an [[immune]] system receptor called [[Toll-like receptor 4]] ([[TLR4]]).<ref>[http://www.nature.com/nature/journal/v484/n7395/full/484419a.html Making morphine work better, Nature 2012, 484: 419]</ref> The morphine-induced TLR4 activation attenuates [[pain]] suppression by [[opioid]] and enhances the development of opioid [[Drug tolerance|tolerance]] and [[addiction]], [[drug abuse]], and other negative side effects such as [[respiratory depression]]. The Yin group has developed drug candidates that can improve opioid-based [[pain management]] therapies.<ref>[http://cen.acs.org/articles/90/web/2012/08/Small-Molecules-Target-Toll-Like.html Drahl, C. Small Molecules Target Toll-Like Receptors, C&EN 2012, 90: 33]</ref> On June 23, 2014, [[BioLineRx]] Ltd. ([[NASDAQ]]: BLRX; [[TASE]]: BLRX) announced that it has in-licensed BL-1010, a novel compound for the treatment of neuropathic pain invented by Yin from the University of Colorado.<ref>{{cite press release|title=BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain|publisher=MarketWatch|url=http://www.marketwatch.com/story/biolinerx-in-licenses-novel-compound-for-treatment-of-neuropathic-pain-2014-06-23}}</ref> In 2015, Yin reported a new drug candidate that could change the way [[Parkinson's disease]] is treated.<ref>{{Cite web |url=http://www.colorado.edu/chem/yinlab/Pages/PDF%20FIles/Science%20Highlights.pdf |title=Making Aggregation Less Aggravating, Science 2015, 348: 769 |access-date=2015-09-24 |archive-url=https://web.archive.org/web/20151125023120/http://www.colorado.edu/chem/yinlab/Pages/PDF%20FIles/Science%20Highlights.pdf |archive-date=2015-11-25 |url-status=dead }}</ref> The drug, called CU-CPT22, may help stop harmful inflammation in certain immune cells that is thought to cause Parkinson's.<ref>{{cite web|title=CU Parkinson's research could revolutionize treatment|url=http://www.thedenverchannel.com/news/cu-parkinsons-research-could-revolutionize-treatment|access-date=2015-09-15|archive-url=https://web.archive.org/web/20150915112724/http://www.thedenverchannel.com/news/cu-parkinsons-research-could-revolutionize-treatment|archive-date=2015-09-15|url-status=dead}}</ref>


==Notes==
==Notes==
Line 55: Line 55:
==References==
==References==
{{reflist}}
{{reflist}}

{{authority control}}


{{DEFAULTSORT:Yin, Hang Hubert}}
{{DEFAULTSORT:Yin, Hang Hubert}}

Latest revision as of 23:25, 9 July 2024

Hang Hubert Yin
Born5 July 1976 (1976-07-05) (age 48)
Alma materYale University
Scientific career
FieldsChemistry, Biology
InstitutionsTsinghua University

Hang Hubert Yin (born 5 July 1976) is a professor and deputy dean of pharmaceutical sciences at Tsinghua University, a recipient of several young scientist awards for his research in chemical biology and drug discovery.[1]

Career

[edit]

Hang Hubert Yin was a pupil at the High School of Peking University. After studying for a bachelor's degree at the Peking University, he received his PhD from Yale University, New Haven in 2004 and then spent a post-doctoral period at the University of Pennsylvania School of Medicine under the supervision of Professor William DeGrado.[2] In 2007, he joined the faculty of the University of Colorado Boulder. His research interests lie at the interface of chemistry, biology, and engineering with particular focuses on structure-based drug design, cell signaling biochemistry, biotechnology development, and membrane protein simulations.[3]

Awards

[edit]

Significant contributions

[edit]

Yin's team showed that morphine causes inflammation by binding to the protein lymphocyte antigen 96, which, in turn, causes the protein to bind to an immune system receptor called Toll-like receptor 4 (TLR4).[12] The morphine-induced TLR4 activation attenuates pain suppression by opioid and enhances the development of opioid tolerance and addiction, drug abuse, and other negative side effects such as respiratory depression. The Yin group has developed drug candidates that can improve opioid-based pain management therapies.[13] On June 23, 2014, BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX) announced that it has in-licensed BL-1010, a novel compound for the treatment of neuropathic pain invented by Yin from the University of Colorado.[14] In 2015, Yin reported a new drug candidate that could change the way Parkinson's disease is treated.[15] The drug, called CU-CPT22, may help stop harmful inflammation in certain immune cells that is thought to cause Parkinson's.[16]

Notes

[edit]

References

[edit]
  1. ^ "Yin Group Website". Archived from the original on 2018-11-07. Retrieved 2018-11-07.
  2. ^ "Yin AACR Bio". Archived from the original on 2012-06-25.
  3. ^ "Yin Research Group Website".
  4. ^ "ACS MEDI".
  5. ^ "Chinese-American Chemistry Professor Association website". Archived from the original on 2013-01-05. Retrieved 2012-08-25.
  6. ^ "SU2C news coverage". YouTube.
  7. ^ "University of Colorado Boulder news coverage". Archived from the original on 2012-07-30. Retrieved 2012-08-25.
  8. ^ "Elion Award lecture" (PDF). Archived from the original (PDF) on 2012-08-03. Retrieved 2012-08-26.
  9. ^ "University of Colorado Technology Transfer Office news coverage". Archived from the original on 2012-12-10.
  10. ^ "University of Colorado Boulder news coverage". Archived from the original on 2012-07-30. Retrieved 2012-08-25.
  11. ^ "Howard Hughes Medical Institute news coverage".
  12. ^ Making morphine work better, Nature 2012, 484: 419
  13. ^ Drahl, C. Small Molecules Target Toll-Like Receptors, C&EN 2012, 90: 33
  14. ^ "BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain" (Press release). MarketWatch.
  15. ^ "Making Aggregation Less Aggravating, Science 2015, 348: 769" (PDF). Archived from the original (PDF) on 2015-11-25. Retrieved 2015-09-24.
  16. ^ "CU Parkinson's research could revolutionize treatment". Archived from the original on 2015-09-15. Retrieved 2015-09-15.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hang_Yin_(scientist)&oldid=1233600792"